Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxo smithkline mexico, s.a. de c.v. - paroxetina (clorhidrato) - paroxetina (clorhidrato)....20,00 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline inc. - paroxetina (clorhidrato hemihidrato) - paroxetina (clorhidrato hemihidrato)....25 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline inc. - paroxetina (clorhidrato hemihidrato) - paroxetina (clorhidrato hemihidrato)....12.5 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline (ireland) limited - paroxetina (clorhidrato hemihidrato) - paroxetina (clorhidrato hemihidrato)....20.00 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - see ingredients - each tablet contains paroxetine hydrochloride equivalent to paroxetine 20,0 mg

Namibia - English - Namibia Medicines Regulatory Council

glaxosmithkline south africa (pty) ltd - paroxetine hydrochloride - tablet - each tablet contains paroxetine hydrochloride equivalent to paroxetine 20,0 mg

United States - English - NLM (National Library of Medicine)

zoetis inc. - melarsomine dihydrochloride (unii: 9cva716q71) (melarsomine - unii:374gj0s41a) - melarsomine dihydrochloride 50 mg in 2 ml - diroban sterile powder for injection is indicated for the treatment of stabilized class 1a , 2b , and 3c heartworm disease caused by immature (4 month-old, stage l5 ) to mature adult infections of dirofilaria immitis in dogs. heartworm disease classification: the following parameters were used to classify the dogs in the clinical field trials for diroban. other parameters may  be considered. as a general rule, conservative treatment should be employed since heartworm disease is serious and potentially fatal. if there is evidence of a high worm burden, patients  should be categorized as class 3. a class 1: patients in this category are characterized as having asymptomatic to mild heartworm  disease. no radiographic signs or signs of anemia are evident. patients with mild disease may have subjective signs such as a general loss of condition, fatigue  on exercise, or occasional cough; however, no objective radiographic or other abnormal laboratory  parameters will be present. b class 2: patients in thi

United States - English - NLM (National Library of Medicine)

a-s medication solutions - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology, clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine in hospitalized depressed patients have not been adequately studied. the efficacy of paroxetine in maintaining

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology, clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine in hospitalized depressed patients have not been adequately studied. the efficacy of paroxetine in maintaining

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology, clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine in hospitalized depressed patients have not been adequately studied. the efficacy of paroxetine in maintaining